Search

Your search keyword '"Hariklia Kranidioti"' showing total 2 results
Start Over Author "Hariklia Kranidioti" Journal liver international
2 results on '"Hariklia Kranidioti"'

1. A typical autoimmune hepatitis (AIH) case following Covid‐19 mRNA vaccination. More than a coincidence?

Author

Anestis Goulas, Spilios Manolakopoulos, Hariklia Kranidioti, and Georgia Kafiri

Subjects
2019-20 coronavirus outbreak, Hepatology, Medication history, Coronavirus disease 2019 (COVID-19), SARS-CoV-2, business.industry, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Vaccination, COVID-19, Alcohol abuse, Autoimmune hepatitis, medicine.disease, Hepatitis, Autoimmune, Immunology, Humans, Medicine, RNA, Messenger, business, Autoantibodies
Abstract

Recently in the Liver International, three patients1,2 with AIH during COVID-19 were reported. Τhere is also increasing evidence that vaccination for SARS-CoV-2 may induce autoimmunity3,4 . Here, we present a case of histologically confirmed AIH after mRNA vaccination against SARS-CoV-2. A 52-years-old Caucasian woman with no medication history or alcohol abuse and normal liver blood tests during previous periodical checkup, received her 1st dose of the Moderna vaccine on 11th of May 2021.

Published
2021
Full Text
View/download PDF

2. Hepatitis B s antigen kinetics during treatment with nucleos(t)ides analogues in patients with hepatitis B e antigen-negative chronic hepatitis B

Author

Melanie Deutsch, Athanasia Striki, Anastasia Kourikou, George V. Papatheodoridis, Emilia Hadziyannis, George Kontos, Hariklia Kranidioti, and Spilios Manolakopoulos

Subjects
Adult, Male, 0301 basic medicine, Hepatitis B virus, medicine.medical_specialty, HBsAg, Antiviral Agents, Gastroenterology, 03 medical and health sciences, Hepatitis B, Chronic, 0302 clinical medicine, Antigen, Telbivudine, Internal medicine, medicine, Adefovir, Humans, Hepatitis B e Antigens, Aged, Proportional Hazards Models, Hepatitis B Surface Antigens, Hepatology, business.industry, virus diseases, Lamivudine, Entecavir, Middle Aged, Hepatitis B, medicine.disease, Virology, digestive system diseases, Kinetics, 030104 developmental biology, HBeAg, DNA, Viral, Female, 030211 gastroenterology & hepatology, business, medicine.drug
Abstract

BACKGROUND/AIMS Serum hepatitis B s antigen (HBsAg) levels might be used as a predictor of virological breakthrough or of sustained off-treatment virological response in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) patients. We evaluated the changes of HBsAg in those patients under nucleos(t)ide analogue(s) [NA(s)] therapy for ≥12 months. METHODS We included 99 HBeAg-negative CHB patients treated with low-genetic barrier NA(s) for a mean of 66 months (lamivudine: 66, adefovir: 6, lamivudine plus adefovir: 11 and telbivudine: 16) and 86 HBeAg-negative CHB patients treated under entecavir or tenofovir for a mean of 30 months as the comparison group. RESULTS Compared to baseline, HBsAg levels decreased by a median of 162, 1525, 943, 1545, 2163 and 3859 IU/mL at 6, 12, 24, 36, 48 and 60 months of therapy with low-genetic barrier NA(s) respectively. The 6-, 12-, 24-, 36-, 48- and 60-month cumulative rates of HBsAg

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results